Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 35


G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer.

Hollmén M, Karaman S, Schwager S, Lisibach A, Christiansen AJ, Maksimow M, Varga Z, Jalkanen S, Detmar M.

Oncoimmunology. 2015 Nov 24;5(3):e1115177. eCollection 2016 Mar.


EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.

De Andrade JP, Park JM, Gu VW, Woodfield GW, Kulak MV, Lorenzen AW, Wu VT, Van Dorin SE, Spanheimer PM, Weigel RJ.

Mol Cancer Ther. 2016 Mar;15(3):503-11. doi: 10.1158/1535-7163.MCT-15-0548-T. Epub 2016 Feb 1.


X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.

Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR.

Cell Death Dis. 2016 Jan 28;7:e2073. doi: 10.1038/cddis.2015.412.


EGFR and HER2 signaling in breast cancer brain metastasis.

Sirkisoon SR, Carpenter RL, Rimkus T, Miller L, Metheny-Barlow L, Lo HW.

Front Biosci (Elite Ed). 2016 Jan 1;8:245-63.


Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas.

Changavi AA, Shashikala A, Ramji AS.

J Lab Physicians. 2015 Jul-Dec;7(2):79-83. doi: 10.4103/0974-2727.163129.


N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

Crozier JA, Advani PP, LaPlant B, Hobday T, Jaslowski AJ, Moreno-Aspitia A, Perez EA.

Clin Breast Cancer. 2016 Feb;16(1):23-30. doi: 10.1016/j.clbc.2015.08.002. Epub 2015 Aug 19.


The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Engström W, Darbre P, Eriksson S, Gulliver L, Hultman T, Karamouzis MV, Klaunig JE, Mehta R, Moorwood K, Sanderson T, Sone H, Vadgama P, Wagemaker G, Ward A, Singh N, Al-Mulla F, Al-Temaimi R, Amedei A, Colacci AM, Vaccari M, Mondello C, Scovassi AI, Raju J, Hamid RA, Memeo L, Forte S, Roy R, Woodrick J, Salem HK, Ryan EP, Brown DG, Bisson WH.

Carcinogenesis. 2015 Jun;36 Suppl 1:S38-60. doi: 10.1093/carcin/bgv030. Review.


Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.

Wu H, Guan S, Sun M, Yu Z, Zhao L, He M, Zhao H, Yao W, Wang E, Jin F, Xiao Q, Wei M.

PLoS One. 2015 May 11;10(5):e0126128. doi: 10.1371/journal.pone.0126128. eCollection 2015.


Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer.

Baker AT, Zlobin A, Osipo C.

Front Oncol. 2014 Dec 12;4:360. doi: 10.3389/fonc.2014.00360. eCollection 2014. Review.


BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.

Kumaraswamy E, Wendt KL, Augustine LA, Stecklein SR, Sibala EC, Li D, Gunewardena S, Jensen RA.

Oncogene. 2015 Aug 13;34(33):4333-46. doi: 10.1038/onc.2014.363. Epub 2014 Nov 24.


Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.

Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E, Kunert R, Jensen-Jarolim E.

Mol Cancer Ther. 2014 Jul;13(7):1777-90. doi: 10.1158/1535-7163.MCT-13-0288. Epub 2014 Apr 22.


Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.

Chen C, Yuan JP, Wei W, Tu Y, Yao F, Yang XQ, Sun JZ, Sun SR, Li Y.

Int J Nanomedicine. 2014 Feb 21;9:1039-48. doi: 10.2147/IJN.S58270. eCollection 2014.


Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Eroglu Z, Tagawa T, Somlo G.

Oncologist. 2014 Feb;19(2):135-50. doi: 10.1634/theoncologist.2013-0283. Epub 2014 Jan 16. Review.


The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients.

Tamaki M, Kamio T, Kameoka S, Kojimahara N, Nishikawa T.

World J Surg Oncol. 2013 Nov 18;11:293. doi: 10.1186/1477-7819-11-293.


Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O.

Clin Cancer Res. 2014 Jan 15;20(2):404-12. doi: 10.1158/1078-0432.CCR-13-1865. Epub 2013 Nov 5.


Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.

Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge M, Gorski SM, Gelmon KA, Bally MB.

PLoS One. 2013 Oct 11;8(10):e76503. doi: 10.1371/journal.pone.0076503. eCollection 2013.


The identification and characterization of breast cancer CTCs competent for brain metastasis.

Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, Goodman JC, Groves MD, Marchetti D.

Sci Transl Med. 2013 Apr 10;5(180):180ra48. doi: 10.1126/scitranslmed.3005109. Erratum in: Sci Transl Med. 2013 Jun 12;5(189):189er5.


Signaling cross-talk in the resistance to HER family receptor targeted therapy.

Yamaguchi H, Chang SS, Hsu JL, Hung MC.

Oncogene. 2014 Feb 27;33(9):1073-81. doi: 10.1038/onc.2013.74. Epub 2013 Apr 1. Review.


Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.

Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G.

Breast Cancer Res Treat. 2012 Dec;136(3):795-804. doi: 10.1007/s10549-012-2315-y. Epub 2012 Nov 4.


Characterization of estrogen-receptor-targeted contrast agents in solution, breast cancer cells, and tumors in vivo.

Pais A, Biton IE, Margalit R, Degani H.

Magn Reson Med. 2013 Jul;70(1):193-206. doi: 10.1002/mrm.24442. Epub 2012 Aug 10.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk